[ Pharmaceutical Sciences Asia - ONLINE ]
Print ISSN 2586-8195 E-ISSN 2586-8470
[ Journal Abbreviation: Pharm.Sci.Asia ]
Mahidol University Journal of Pharmaceutical Sciences
  FORMER NAME   "Mahidol University Journal of Pharmaceutical Sciences" Published Since 1974

 
Abstracts

DOI: 10.29090/psa.2020.03.019.0040Pharm Sci Asia ; 47(3), 246-252
 

Health utility score in type 2 diabetes mellitus

Tri Murti Andayani1*, Susi Ari Kristina2, Dwi Endarti2, Septiana Tri Wahyuni3, Anindya Rahmawati3

1 Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia
2 Department of Pharmaceutics, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia
3 Master Program in Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia


Cost-utility analysis requires data of severity-based health utility score for calculating the Quality adjusted life years. This study aims to figure out utility scores based on complications, comorbidities and diabetes treatments in patients with type 2 diabetes mellitus.

The study was conducted using cross-sectional design in patients with type 2 diabetes mellitus who visited regional hospitals in Yogyakarta, Indonesia. Utility score was measured using EQ-5D-5L questionnaire. The scoring was performed using a value set developed for the Indonesian population.

The results of the study in 418 patients with diabetes mellitus with an average age of 60.74 (SD=8.61) years showed that the utility score and the average Visual analog scale (VAS) value were 0.74 (SD=0.22) and 74.60 (SD=12.23) respectively. Problems related to the mobility were reported in 42.67% of the patients, while for self-care domain in 11%, daily activity in 48%, pain/uncomfortable in 76.33%, and anxiety/depression in 44.33%. There were significant differences in the utility score based on complications related to DM, that the mean utility score of DM patients without complications was 0.79 (SD=0.16), with microvascular complications was 0.76 (SD=0.19), with macrovascular complications was 0.71 (SD=0.19) and with microvascular and macrovascular complications was 0.59 (SD=0.31). The lowest utility score was in the patients with stroke complications by 0.43 (SD=0.32). The differences in the therapeutic regimens given also indicated the different utility scores. Diabetes mellitus patients with complications showed lower utility scores. Health utility scores based on complications could be used as a supporting data in the pharmacoeconomic analysis.



Keyword:

Health utility score; Diabetes mellitus; EQ5D5L questionnaire




Download full paper (PDF File size: 898.61 KB.)





Vol.47
No.3
July - September 2020

See other volume

 


Vol.47
No.2
April - June 2020

See other volume

 


Vol.47
No.1
January - March 2020

See other volume

 
 
 

Home
Aims and Scope
Editorial Board
Publication Ethics
Instruction to Authors
Announcement
All Volumes & Issues
Submit Online
Contact us
   
Search
   
Faculty of Pharmacy Mahidol University
Mahidol University
Member's menu

You're now loging on with following account:
Guest (unknown)

Please Sign in or Register



    Copyright © 2017
    Faculty of Pharmacy, Mahidol University, THAILAND